Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | CASR | P41180 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6480871 | 1.00 | BACE1 (0.40) | BACE1ADRB3ADRB1ALDH1A1ABCB1 | |
| SCHEMBL6478954 | 0.91 | KMT2A (0.41) | BACE1ADRB3ADRB1ALDH1A1ABCB1 | |
| SCHEMBL6479079 | 0.91 | RAB9A (0.41) | BACE1ALDH1A1 | |
| SCHEMBL6480769 | 0.91 | RAB9A (0.41) | BACE1ALDH1A1 | |
| SCHEMBL6491686 | 0.88 | PTPN1 (0.40) | BACE1ADRB3ADRB1ALDH1A1CYP2D6 | |
| SCHEMBL6488382 | 0.88 | MEN1 (0.47) | BACE1ADRB3ADRB1ALDH1A1LMNA | |
| SCHEMBL6488383 | 0.88 | MEN1 (0.47) | BACE1ADRB3ADRB1ALDH1A1LMNA | |
| SCHEMBL6538543 | 0.85 | BACE1 (0.43) | BACE1ADRB3ADRB1ABCB1CYP2D6 | |
| SCHEMBL6540224 | 0.85 | BACE1 (0.43) | BACE1ADRB3ADRB1ABCB1CYP2D6 | |
| SCHEMBL6539067 | 0.80 | ADRB1 (0.49) | BACE1ADRB3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043358-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-02-24 | — | — | US | disclosed |
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB1, ADRB2, ADRB3 | BACE1 2044/4885ADRB3 3/4885ADRB1 1/4885 |
| US-20050043358-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB2, ADRB1, ADRB3 | BACE1 1612/4885ADRB3 3/4885ADRB1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.